The Metabolic MASH-UP – What’s New and What’s Hot
Description
The rising tide of metabolic disease has triggered a concurrent epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Despite this growing clinical burden, critical gaps remain in clinical awareness regarding disease prevalence, long-term consequences, effective risk assessment, and evidence-based management. With multiple novel therapeutic agents rapidly advancing through clinical trials for MASH, it is essential for clinicians to stay updated on these emerging treatment paradigms. Join us in this live exchange with the experts in the field to: Interpret emerging clinical data regarding new and developmental therapies for MASH. Develop individualized treatment strategies tailored to a patient's specific degree of liver fibrosis, steatosis, and concurrent metabolic comorbidities.
- CE: 1.25 CME Hours
- Supported by: Inventiva
- Organized by: Medscape Education
- For more information and to register, visit: https://events.medscapelive.org/website/97867/
